Cervical Cancer - Global Clinical Trial Landscape (2024)

The cervical cancer (CC) clinical trial landscape is robust, with over 1,300 trials initiated since 2019, primarily in Asia-Pacific and North America. Promising candidates in the drug development pipeline target various aspects of the disease using bispecific or multispecific antibodies, small molecules, antibody-drug conjugates, and preventive vaccines. In terms of funding, Public and NGO support is increasingly directed toward improving vaccination, screening, and treatment access in low- and middle-income countries. In this text, we dive further into various aspects of the CC clinical trial landscape and the burden it has caused in different locations worldwide.